Uli Stilz

Uli Stilz is the Head of the Novo Nordisk Bio Innovation Hub, where he leads a team focused on developing innovative partnerships to create new therapies for cardiometabolic and rare diseases.  Uli has contributed to over 60 preclinical and clinical drug candidates across various therapeutics areas. Uli has a master’s degree from ETH Zürich and a Ph.D. from the Max-Planck-Institute of Biochemistry. After postdoctoral studies at the California Institute of Technology, he worked at Hoechst AG and later joined Sanofi as Associate Vice President of the Innovation unit within the Diabetes Division.